Why Embecta Corp.’s (EMBC) Stock Is Up 6.98%
As of Monday, September 14, Embecta Corp.’s EMBC share price has surged by 6.98%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company’s products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient’s diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
Commentary & Analysis
Why Embecta Corp.’s (EMBC) Stock Is Down 5.50%
As of Wednesday, September 09, Embecta Corp.’s EMBC share price has dipped by 5.50%, which has investors questioning if this is right time to buy.Michael Rose
Why Embecta Corp.’s (EMBC) Stock Is Up 5.43%
As of Wednesday, September 02, Embecta Corp.’s EMBC share price has surged by 5.43%, which has investors questioning if this is right time to sell.Michael Rose
Is Embecta Corp. (EMBC) Overvalued?
We dive into why Embecta Corp. (EMBC) could be considered overvalued on 2026-08-18, based on AAII’s Value Score and Grade.Rosalio Madrigal
Why Embecta Corp.’s (EMBC) Stock Is Up 5.78%
As of Wednesday, August 19, Embecta Corp.’s EMBC share price has surged by 5.78%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | EMBC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $288.4 | $373.7 | 31% |
|
| Shares Out (Mil) | 58.5 | 40.8 | 51% |
|
| Institutional Ownership | 96.5% | 83.6% | 70% |
|
| Float (Mil) | 54.8 | 34.7 | 49% |
|
| Beta | 0.79 | 0.88 | 47% |
|
| Avg Daily Volume (000s) | 1,256 | 266 | 75% |
|
| Price Change (52-week) |
(66.1%) | 62.5% | 11% |
|
| Growth | EMBC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (0.1%) | 11.8% | 17% |
|
| Net Income (5yr) | (25.9%) | (5.8%) | 16% |
|
| EPS (5yr) | (26.4%) | 10.4% | 10 |
|
| Dividends (5yr) | 0.0% | 0.0% | 68% |
|
| Cash Flow (5yr) | na | (15.5%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | $0.290 | $1.835 | $1.763 | |
| Month Ago EPS | $0.290 | $1.835 | $1.763 | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 3 | 1 | 1 | |
| Three Months Ago EPS | $0.353 | $1.597 | $1.740 | |
| Year/Year Chg | (19.4%) | 13.3% | 20.4% | |
| Financials | EMBC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,019 | $119 | 50% |
|
| Net Income (TTM) (Mil) | $88 | ($9) | 59% |
|
| EPS (TTM) | $1.489 | ($0.400) | 66% |
|
| Operating Cash Flow (TTM) (Mil) | $174 | ($3) | 57% |
|
| Net Cash Flow (TTM) (Mil) | ($15) | $1 | 28% |
|
| Long-Term Debt (Q1) (Mil) | $1,352 | $23 | 69% |
|
| Enterprise Value (Q1) (Mil) | $1,583 | $371 | 46% |
|
| Valuation | EMBC | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.80 | na |
|
| P/E | 3.5 | 25.5 | 3% |
|
| Dividend Yield | 0.8% | 0.0% | 65% |
|
| PEG (5yr hist) | na | 1.4 | na |
|
| Ratios | EMBC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 58.4% | 58.3% | 71% |
|
| Net Margin | 8.6% | (6.9%) | 59% |
|
| ROA | 7.2% | (12.7%) | 80% |
|
| ROE | (13.6%) | (12.3%) | 26% |
|
| Liabilities to Assets | 148.4% | 46.0% | 98% |
|
| F-Score | 6 | 4 | na |
|
Embecta Corp. did not pass any screens on 9/15/2026.
